Pharmanutra Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Roberto Lacorte

İcra Kurulu Başkanı

€1.9m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

CEO

Roberto Lacorte (55 yo)

no data

Görev süresi

€1,918,290

Tazminat

Mr. Roberto Lacorte serves as Vice Chairman, Managing Director and Vice President of Pharmanutra S.p.A. Between January 1995 and April 1996, Mr. Lacorte carried out military service with the Marines. Betwe...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Andrea Lacorte	Chairman & President	no data	€2.19m	Veri yok
Roberto Lacorte	Vice Chairman	no data	€1.92m	0.15% € 762.2k
Carlo Volpi	Delegate Advisor	no data	€1.77m	10.56% € 55.1m
Germano Tarantino	Scientific Director & Executive Director	12.7yrs	€586.16k	Veri yok
Marida Zaffaroni	Independent Director	no data	€41.00k	Veri yok
Alessandro Calzolari	Lead Independent Director	no data	€41.00k	Veri yok
Giovanna Zanotti	Independent Director	no data	€41.00k	Veri yok
Debora Mazzacherini	Standing Auditor	no data	Veri yok	Veri yok
Michele Giordano	President of Supervisory Board	less than a year	Veri yok	Veri yok
Pasquale Giovinazzo	Internal Member of Supervisory Board	less than a year	Veri yok	Veri yok

0.7yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PHNM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.7 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Pharmanutra Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Pharmanutra S.p.A. to Report Fiscal Year 2023 Results on Mar 15, 2024

Less than half of directors are independent

First quarter 2023 earnings released

Upcoming dividend of €0.80 per share at 1.6% yield

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: EPS: €1.56 (vs €1.42 in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

Pharmanutra S.p.A. to Report Fiscal Year 2022 Results on Mar 16, 2023

Less than half of directors are independent

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: €0.49 (vs €0.47 in 2Q 2021)

Less than half of directors are independent

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million.

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

PharmaNutra S.P.A. Announces European Union Authorises Marketing of CFAs as Novel Food

Less than half of directors are independent

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş